Replies to post #2773 on Biotech Values

[masterlongevity]

Avastin failed in 3rd line MBC.

Avastin has failed in 3rd line CRC as well.

Avastin has shown activity in MBC, NSCLC, RCC, pancreatic cancer, MDS, NHL

Avastin succeeded with flying colors in 1st line CRC


Is it unreasonable to believe that Avastin will pass the muster in 1st line MBC?

we are now speaking semantics, but if the potential market for a new indication is over 250 million, I consider that pipeline material.

[rkrw]

For some I would agree, others not but I can agree to disagree on the semantics :-)

<<<but i just don't consider these label expansions as the pipeline. I'm putting my foot down on this one... :-)>>>

At least that way if genr gets approval for amd everyone would stop talking about the cancer indication :-)